Benitec Biopharma (BNTC) Capital Expenditures (2020 - 2025)

Benitec Biopharma has reported Capital Expenditures for 5 years, with the latest figure at $18000.0 in Q1 2025.

• Quarterly Capital Expenditures changed N/A year-over-year to $18000.0 in Q1 2025, while the trailing twelve-month figure through Jun 2025 was $19000.0 (up 35.71% YoY) and the FY2025 annual result came in at $18000.0, down 89.94% from the prior year.
• Capital Expenditures improved to $18000.0 in Q1 2025 per BNTC's latest filing, from $1000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $18000.0 in Q1 2025 and troughed at -$141000.0 in Q2 2021.
• A 4-year average of -$18800.0 and a median of $13000.0 in 2022 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2021 and 2022: Capital Expenditures tumbled 1184.62% in 2021, then soared 109.22% in 2022.
• Over 4 years, Capital Expenditures stood at -$141000.0 in 2021, then jumped by 109.22% to $13000.0 in 2022, then plunged by 92.31% to $1000.0 in 2023, then soared by 1700.0% to $18000.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $18000.0, $1000.0, and $13000.0 for Q1 2025, Q2 2023, and Q2 2022 respectively.